桂林三金(002275.SZ)：目前公司产品BC006单抗注射液项目，即将完成I期临床试验。

Core Viewpoint - Guilin Sanjin (002275.SZ) is nearing the completion of Phase I clinical trials for its product BC006 monoclonal antibody injection [1] Company Summary - The company has announced on its investor interaction platform that the BC006 monoclonal antibody injection project is about to finish its Phase I clinical trials [1]